Pathways to Antimicrobial Clinical Efficacy (PACE) | 2024 Diagnostic Innovations
Event details
| Date | 30.10.2024 |
| Category | Call for proposal |
Aim: Projects should aim to address unmet diagnostic needs for bacterial infections with the highest burden of antimicrobial resistance, with the objective to:
Funding: up to £300K for technical feasibility projects (TRL 3) and up to £1M for product development projects (TRL 4-5)
Eligibility: Open to researchers in academia and small to medium enterprises (SMEs) worldwide, including consortia (large diagnostic industry partners permitted, but must cover own costs). Applications should have a single lead applicant, however co-applications are welcome
How to Apply: Applications must be sent through PACE’s online platform.
Deadline Expression of Interest: 30 October 2024
Further information
- Reduce inappropriate antibiotic prescriptions.
- Provide faster results to indicate which antibiotic should be used.
- Catalyse the move to personalised, narrow-spectrum treatments.
- Urinary Tract Infections (UTI) - focusing on rapid tests suitable for use in level 1 healthcare settings that can i) identify whether a bacterial infection is present and/or ii) identify the most appropriate treatment and, ideally, the underlying pathogens(s). Innovative solutions for use at-home or in the community setting are also encouraged.
- Lower Respiratory Tract Infections (LRTI) - focusing on rapid tests to identify the presence of a bacterial infection applicable to level 1 healthcare settings, community care and hospital triage settings. Rapid, near-patient tests that identify the most appropriate treatment and, ideally, the underlying pathogen for pneumonia applicable to primary care or hospital settings will be prioritised, as will minimally invasive/burdonsome sample types.
- Bloodstream Infections (BSI)/Sepsis - focusing on hospital-based tests that can provide faster identification of pathogens and antibiotic susceptibility profile for suspected BSI/sepsis cases direct from sample. This includes diagnostic innovation for detection and management of the bacterial component of neonatal sepsis.
Funding: up to £300K for technical feasibility projects (TRL 3) and up to £1M for product development projects (TRL 4-5)
Eligibility: Open to researchers in academia and small to medium enterprises (SMEs) worldwide, including consortia (large diagnostic industry partners permitted, but must cover own costs). Applications should have a single lead applicant, however co-applications are welcome
How to Apply: Applications must be sent through PACE’s online platform.
Deadline Expression of Interest: 30 October 2024
Further information
- More information about the call is available here
- Application portal available here
- For any other questions, please contact the Research Office.
Practical information
- General public
- Free